{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T03:05:25Z","timestamp":1709262325226},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1007\/bf03259802","type":"journal-article","created":{"date-parts":[[2012,12,28]],"date-time":"2012-12-28T11:53:09Z","timestamp":1356695589000},"page":"127-136","source":"Crossref","is-referenced-by-count":0,"title":["Effect of Food on the Pharmacokinetic Profile of Etamicastat (BIA 5-453)"],"prefix":"10.1007","volume":"11","author":[{"given":"Manuel","family":"Vaz-da-Silva","sequence":"first","affiliation":[]},{"given":"Teresa","family":"Nunes","sequence":"additional","affiliation":[]},{"given":"Jos\u00e9 F.","family":"Rocha","sequence":"additional","affiliation":[]},{"given":"Amilcar","family":"Falc\u00e3o","sequence":"additional","affiliation":[]},{"given":"Luis","family":"Almeida","sequence":"additional","affiliation":[]},{"given":"Patricio","family":"Soares-da-Silval","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2012,11,27]]},"reference":[{"issue":"7Suppl.4","key":"BF03259802_CR1","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/00005344-200000004-00001","volume":"35","author":"M. Esler","year":"2000","unstructured":"Esler M, Kaye D. Sympathetic nervous system activation in essential hypertension, cardiac failure and psychosomatic heart disease. J Cardiovasc Pharmacol 2000; 35 (7 Suppl. 4): S1\u20137","journal-title":"J Cardiovasc Pharmacol"},{"issue":"12","key":"BF03259802_CR2","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.ejheart.2008.09.013","volume":"10","author":"G. Grassi","year":"2008","unstructured":"Grassi G, Bolla G, Quarti-Trevano F, et al. Sympathetic activation in congestive heart failure: reproducibility of neuroadrenergic markers. Eur J Heart Fail 2008 Dec; 10 (12): 1186\u201391","journal-title":"Eur J Heart Fail"},{"issue":"5","key":"BF03259802_CR3","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1113\/expphysiol.2009.047381","volume":"95","author":"G. Grassi","year":"2010","unstructured":"Grassi G, Seravalle G, Quarti-Trevano F. The \u2018neuroadrenergic Hypothesis\u2019 in hypertension: current evidence. Exp Physiol 2010; 95 (5): 581\u20136","journal-title":"Exp Physiol"},{"issue":"4","key":"BF03259802_CR4","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/01.AACN.0000340718.93742.c4","volume":"19","author":"C.S. Lee","year":"2008","unstructured":"Lee CS, Tkacs NC. Current concepts of neurohormonal activation in heart failure: mediators and mechanisms. AACN Adv Crit Care 2008 Oct\u2013Dec; 19 (4): 364\u201385","journal-title":"AACN Adv Crit Care"},{"issue":"4Pt2","key":"BF03259802_CR5","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1161\/01.HYP.34.4.724","volume":"34","author":"G. Mancia","year":"1999","unstructured":"Mancia G, Grassi G, Giannattasio C, et al. Sympathetic activation in the pathogenesis of hypertension and progression of organ damage. Hypertension 1999; 34 (4 Pt 2): 724\u20138","journal-title":"Hypertension"},{"issue":"8","key":"BF03259802_CR6","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1002\/clc.4960180804","volume":"18","author":"W.W. Parmley","year":"1995","unstructured":"Parmley WW. Neuroendocrine changes in heart failure and their clinical relevance. Clin Cardiol 1995; 18 (8): 440\u20135","journal-title":"Clin Cardiol"},{"issue":"21","key":"BF03259802_CR7","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJM199605233342109","volume":"334","author":"M.A. Pfeffer","year":"1996","unstructured":"Pfeffer MA, Stevenson LW. Beta-adrenergic blockers and survival in heart failure. N Engl J Med 1996; 334 (21): 1396\u20137","journal-title":"N Engl J Med"},{"issue":"8","key":"BF03259802_CR8","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1038\/sj.bjp.0701315","volume":"121","author":"W.C. Stanley","year":"1997","unstructured":"Stanley WC, Li B, Bonhaus DW, et al. Catecholamine modulatory effects of nepicastat (RS-25560-197), a novel, potent and selective inhibitor of dopamine-beta-hydroxylase. Br J Pharmacol 1997; 121 (8): 1803\u20139","journal-title":"Br J Pharmacol"},{"key":"BF03259802_CR9","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/0024-3205(64)90031-1","volume":"3","author":"M. Goldstein","year":"1964","unstructured":"Goldstein M, Anagnoste B, Lauber E, et al. Inhibition of dopamine-beta-hydroxylase by disulfiram. Life Sci 1964; 3: 763\u20137","journal-title":"Life Sci"},{"issue":"10","key":"BF03259802_CR10","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1016\/0006-2952(69)90366-9","volume":"18","author":"W. Lippmann","year":"1969","unstructured":"Lippmann W, Lloyd K. Dopamine-\u03b2-hydroxylase inhibition by dimethyldithiocarbamate and related compounds. Biochem Pharmacol 1969; 18 (10): 2507\u201316","journal-title":"Biochem Pharmacol"},{"issue":"5297","key":"BF03259802_CR11","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/231054a0","volume":"231","author":"H. Hidaka","year":"1971","unstructured":"Hidaka H. Fusaric (5-butylpicolinic) acid, an inhibitor of dopamine beta-hydroxylase, affects serotonin and noradrenaline. Nature 1971; 231 (5297): 54\u20135","journal-title":"Nature"},{"issue":"1","key":"BF03259802_CR12","first-page":"80","volume":"171","author":"G.A. Johnson","year":"1970","unstructured":"Johnson GA, Boukma SJ, Kim EG. In vivo inhibition of dopamine beta-hydroxylase by 1-phenyl-3-(2-thiazolyl)-2-thiourea (U-14,624). J Pharmacol Exp Ther 1970; 171 (1): 80\u20137","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"BF03259802_CR13","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1021\/jm051051f","volume":"49","author":"A. Beliaev","year":"2006","unstructured":"Beliaev A, Learmonth DA, Soares-da-Silva P. Synthesis and biological evaluation of novel, peripherally selective chromanyl imidazolethione-based inhibitors of dopamine betahydroxylase. J Med Chem 2006; 49 (3): 1191\u20137","journal-title":"J Med Chem"},{"key":"BF03259802_CR14","first-page":"e133","volume":"50","author":"B. Igreja","year":"2007","unstructured":"Igreja B, Wright L, Soares-da-Silva P. Sustained antihypertensive effects of a selective peripheral dopamine-\u03b2-hydroxylase inhibitor [abstract]. Hypertension 2007; 50: e133","journal-title":"Hypertension"},{"key":"BF03259802_CR15","first-page":"087P","volume":"6","author":"B. Igreja","year":"2008","unstructured":"Igreja B, Wright L, Soares-da-Silva P. Long-term lowering of blood pressure levels in the SHR by selective peripheral inhibition of dopamine-b-hydroxylase with BIA 5-453 [abstract]. pA2 Online 2008; 6: 087P","journal-title":"pA2 Online"},{"key":"BF03259802_CR16","first-page":"088P","volume":"6","author":"L. Wright","year":"2008","unstructured":"Wright L, Soares-da-Silva P. Long-term benefits of the selective peripheral dopamine-\u03b2-hydroxylase inhibitor BIA 5-453 in heart failure [abstract]. pA2 Online 2008; 6: 088P","journal-title":"pA2 Online"},{"key":"BF03259802_CR17","unstructured":"Data on file, BIAL, 2008"},{"issue":"Suppl.1","key":"BF03259802_CR18","first-page":"39","volume":"40","author":"B. Igreja","year":"2009","unstructured":"Igreja B, Loureiro AI, Fernandes-Lopes C, et al. Interspecies differences in pharmacodynamic and disposition of BIA 5-453, a novel dopamine-\u03b2-hydroxylase inhibitor [abstract]. Drug Metabol Rev 2009; 40 Suppl. 1: 39\u201340","journal-title":"Drug Metabol Rev"},{"key":"BF03259802_CR19","volume-title":"J Clin Pharmacol","author":"J.F. Rocha","year":"2011","unstructured":"Rocha JF, Vaz-da-Silva M, Nunes T, et al. Single-dose tolerability, pharmacokinetics and pharmacodynamics of etamicastat (BIA 5-453), a new dopamine \u03b2-hydroxylase inhibitor, in healthy subjects. J Clin Pharmacol. Epub 2011 Feb 22"},{"issue":"4","key":"BF03259802_CR20","first-page":"255","volume":"10","author":"T. Nunes","year":"2010","unstructured":"Nunes T, Rocha JF, Vaz-da-Silva M, et al. Safety, tolerability and pharmacokinetics of etamicastat, a novel dopamine-\u03b2-hydroxylase inhibitor, in a rising multiple-dose study in young healthy subjects. Drugs R D 2010; 10 (4): 255\u201342","journal-title":"Drugs R D"},{"key":"BF03259802_CR21","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1124\/dmd.104.002998","volume":"33","author":"H.R. Winter","year":"2005","unstructured":"Winter HR, Unadkat JD. Identification of cytochrome P450 and arylamine N-acetyltransferase isoforms involved in sulfadiazine metabolism. Drug Metab Dispos 2005; 33: 969\u201376","journal-title":"Drug Metab Dispos"},{"issue":"9","key":"BF03259802_CR22","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1093\/carcin\/22.9.1405","volume":"22","author":"S. Fronhoffs","year":"2001","unstructured":"Fronhoffs S, Bruning T, Ortiz-Pallardo E, et al. Real-time PCR analysis of the N-acetyltransferase NAT1 allele *3, *4, *10, *11, *14 and *17 polymorphismin squamous cell cancer of head and neck. Carcinogenesis 2001Sep; 22 (9): 1405\u201312","journal-title":"Carcinogenesis"},{"issue":"1","key":"BF03259802_CR23","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/carcin\/bgi171","volume":"27","author":"D. Li","year":"2006","unstructured":"Li D, Jiao L, Li Y, et al. Polymorphisms of cytochrome P4501A2 and N-acetyltransferase genes, smoking, and risk of pancreatic cancer. Carcinogenesis 2006 Jan; 27 (1): 103\u201311","journal-title":"Carcinogenesis"},{"issue":"6","key":"BF03259802_CR24","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1159\/000072934","volume":"16","author":"H. Brocvielle","year":"2003","unstructured":"Brocvielle H, Muret P, Goydadin AC, et al. N-acetyltransferase 2 acetylation polymorphism: prevalence of slow acetylators does not differ between atopic dermatitis patients and healthy subjects. Skin Pharmacol Appl Skin Physiol 2003 Nov\u2013Dec; 16 (6): 386\u201392","journal-title":"Skin Pharmacol Appl Skin Physiol"},{"issue":"1","key":"BF03259802_CR25","first-page":"22","volume":"58","author":"M. Rychlik-Sych","year":"2006","unstructured":"Rychlik-Sych M, Skretkowicz J, Gawronska-Szklarz B, et al. Acetylation genotype and phenotype in patients with systemic lupus erythematosus. Pharmacol Rep 2006 Jan\u2013Feb; 58 (1): 22\u20139","journal-title":"Pharmacol Rep"},{"key":"BF03259802_CR26","unstructured":"FDA\/CDER. Guidance for industry (draft). Food-effect bioavailability and fed bioequivalence studies. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), 2002 [online]. Available from URL: http:\/\/www.fda.gov\/downloads\/RegulatoryInformation\/Guidances\/UCM126833.pdf [Accessed 2011 Apr 11]"},{"key":"BF03259802_CR27","unstructured":"EMEA\/CPMP. Note for guidance on the investigation of bioavailability and bioequivalence. CPMP\/EWP\/1401\/98, European Agency for the Evaluation of Medicinal Products, Committee for ProprietaryMedicinal Products (CPMP), 2001 [online]. Available from URL: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500003011.pdf [Accessed 2011 Apr 11]"},{"key":"BF03259802_CR28","unstructured":"FDA\/CDER. Guidance for industry. Bioavailability and bioequivalence studies for orally administered drug products- general considerations. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), 2003 [online]. Available from URL: http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM070124.pdf [Accessed 2011 Apr 11]"},{"key":"BF03259802_CR29","unstructured":"FDA\/CDER. Guidance for industry, Bioanalytical method validation. US Department of Health and Human Services, Food and Drug Administration. Center for Drug Evaluation and Research (CDER). Center for Veterinary Medicine, 2001 [online]. Available from URL: http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM070107.pdf [Accessed 2011 Apr 11]"},{"key":"BF03259802_CR30","unstructured":"EMEA\/CPMP. Note for guidance on the investigation of drug interactions. CPMP\/EWP\/560\/95, European Agency for the Evaluation of Medicinal Products, Committee for Proprietary Medicinal Products (CPMP). 1997 [online]. Available from URL: http:\/\/www.tga.gov.au\/docs\/pdf\/euguide\/ewp\/056095en.pdf [Accessed 2011 Apr 11]"}],"container-title":["Drugs in R & D"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1007\/BF03259802","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,21]],"date-time":"2017-06-21T04:57:31Z","timestamp":1498021051000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF03259802"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["BF03259802"],"URL":"https:\/\/doi.org\/10.1007\/bf03259802","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,6]]}}}